

## History of Changes for Study: NCT00509795

### Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Macular Degeneration(AMD) (VIEW1)

[Latest version \(submitted December 20, 2012\) on ClinicalTrials.gov](#)

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side comparison format applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently selected.
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in **red**.
- Study additions are displayed in **green**.

### Study Record Versions

Version	A	B	Submitted Date	Changes
1	<input type="radio"/>	<input type="radio"/>	<a href="#">July 31, 2007</a>	None (earliest Version on record)
2	<input type="radio"/>	<input type="radio"/>	<a href="#">August 17, 2007</a>	Recruitment Status, Study Status and Contacts/Locations

<https://clinicaltrials.gov/ct2/history/NCT00509795?A=8&B=9&C=merged#StudyPageTop>

1/7/2021

History of Changes for Study: NCT00509795

Version	A	B	Submitted Date	Changes
3	<input type="radio"/>	<input type="radio"/>	<a href="#">November 14, 2007</a>	Contacts/Locations and Study Status
4	<input type="radio"/>	<input type="radio"/>	<a href="#">December 4, 2007</a>	Study Status and Contacts/Locations
5	<input type="radio"/>	<input type="radio"/>	<a href="#">March 13, 2008</a>	Study Status and Eligibility
6	<input type="radio"/>	<input type="radio"/>	<a href="#">June 26, 2008</a>	Contacts/Locations, Arms and Interventions, Study Design, Study Status, Outcome Measurement and Identification
7	<input type="radio"/>	<input type="radio"/>	<a href="#">January 22, 2009</a>	Contacts/Locations, Study Status, Arms and Interventions, Outcome Measures, Eligibility and Sponsor/Collaborators
8	<input checked="" type="radio"/>	<input type="radio"/>	<a href="#">March 3, 2009</a>	Study Status and Contacts/Locations
9	<input type="radio"/>	<input checked="" type="radio"/>	<a href="#">April 28, 2009</a>	Outcome Measures, Arms and Interventions, Study Status, Eligibility, Conditions and Study Design
10	<input type="radio"/>	<input type="radio"/>	<a href="#">September 12, 2009</a>	Recruitment Status, Study Status and Contacts/Locations
11	<input type="radio"/>	<input type="radio"/>	<a href="#">December 1, 2009</a>	Study Status, Contacts/Locations and Sponsor/Collaborators
12	<input type="radio"/>	<input type="radio"/>	<a href="#">January 5, 2011</a>	Study Status
13	<input type="radio"/>	<input type="radio"/>	<a href="#">April 18, 2011</a>	Study Status and Study Design
14	<input type="radio"/>	<input type="radio"/>	<a href="#">May 4, 2011</a>	Study Status
15	<input type="radio"/>	<input type="radio"/>	<a href="#">December 1, 2011</a>	Recruitment Status, Study Status and Sponsor/Collaborators
16	<input type="radio"/>	<input type="radio"/>	<a href="#">April 13, 2012</a>	Arms and Interventions, Outcome Measures, Study Status, More Information, Reported Adverse Events, Baseline Characteristics, Participant Flow, Eligibility, Study Description and Study Identification
17	<input type="radio"/>	<input type="radio"/>	<a href="#">December 17, 2012</a>	Reported Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow and Study Status
18	<input type="radio"/>	<input type="radio"/>	<a href="#">December 20, 2012</a>	Outcome Measures, References and Study Status

<https://clinicaltrials.gov/ct2/history/NCT00509795?A=8&B=9&C=merged#StudyPageTop>

1/7/2021

History of Changes for Study: NCT00509795

Compare

Comparison Format:  Merged  
 Side-by-Side

[Scroll up to access the controls](#)

Changes (Merged) for Study: NCT00509795  
March 3, 2009 (v8) -- April 28, 2009 (v9)

Compare v7 to v8

Changes in: [Outcome Measures](#), [Arms and Interventions](#), [Study Status](#), [Eligibility](#), [Conditions](#) and [Study](#)

Show only changed modules

### Study Identification

Unique Protocol ID: VGFT-OD-0605

Brief Title: ~~Double-Masked Study of Efficacy and Safety of IVT VEGF Trap Eye in Subjects With Wet Age-Related Macular Degeneration (AMD) (VIEW1)~~ *Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Subjects With Wet Age-Related Macular Degeneration(AMD) (VIEW1)*

Official Title: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration

Secondary IDs:

### Study Status

Record Verification: ~~March 2009~~ April 2009

Overall Status: Recruiting

Study Start: August 2007

Primary Completion: ~~October 2010~~ December 2011 [Anticipated]

Study Completion: ~~January 2012~~ December 2011 [Anticipated]

First Submitted: July 31, 2007

<https://clinicaltrials.gov/ct2/history/NCT00509795?A=8&B=9&C=merged#StudyPageTop>

First Submitted that July 31, 2007

Met QC Criteria:

First Posted: August 1, 2007 [Estimate]

Last Update Submitted that ~~March 3, 2009~~ April 28, 2009

Met QC Criteria:

Last Update Posted: ~~March 5~~ April 29, 2009 [Estimate]

#### Sponsor/Collaborators

Sponsor: Regeneron Pharmaceuticals

Responsible Party:

Collaborators: Bayer

#### Oversight

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

Data Monitoring: Yes

#### Study Description

Brief Summary: This study is a phase III, double-masked, randomized, study of the efficacy and safety of ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration. Approximately 1000 patients will be randomized in the US and Canada.

Detailed Description:

#### Conditions

Conditions: ~~Neovascular Age-Related~~ Macular Degeneration

Keywords:

#### Study Design

Study Type: Interventional

Primary Purpose: Treatment

1/7/2021

History of Changes for Study: NCT00509795

Study Phase: Phase 3

Interventional Study Model: Parallel Assignment

Number of Arms: 4

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Allocation: Randomized

Enrollment: 1200 [Anticipated]

### Arms and Interventions

Arms	Assigned Interventions
------	------------------------

<https://clinicaltrials.gov/ct2/history/NCT00509795?A=8&B=9&C=merged#StudyPageTop>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.